The Right Medication to the Right Patient
A team of former senior directors from big pharma with combined 60+ years and more than 60 projects in diagnostics and 505(b)(2) drug development have secured exclusive worldwide rights to a high value asset, made available by a recent well-publicized R&D restructuring and divestment.
Escitalopram LAI (Long Acting Injectable)
An early stage asset at formulation stage. With the discovery and patenting of a novel salt to Escitalopram we can bring the first SSRI depot to the market.
First depot injection for SSRI for a vast depression market estimated at $15.8Bn in 2025
505(b)(2) truncated development with LOE Q4 2038. Opportunity to out-license end of phase I
Estimated potential peak sales of over $1.5Bn (US and EU big 5)
Why 428 Pharma?
Experienced pharma team with over 60 projects between the team in the area of diagnostics and 505(b)(2) drug development